Report #2858240

Overview

Sex

Unknown

Age

Age unknown

State

—

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

Lymphoedema; This is a spontaneous report received from a Consumer or other non HCP. Other Case identifier(s): MOD-2025-789109 (Moderna). A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; elasomeran (SPIKEVAX), as dose number unknown, single intramuscular for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LYMPHOEDEMA (non-serious), outcome "unknown". Additional information: It was reported that On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form and dose of Tozinameran (Pfizer BioNTech COVID-19 vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced LYMPHOEDEMA (lymphedema). At the time of the report, lymphedema outcome was unknown. The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) was unknown. No concomitant medications were reported. The patient had been recently diagnosed with lymphedema and needed to get covid vaccines within the next few weeks and wanted to know if it was safe to get the Spikevax vaccine since had both Moderna and Pfizer. It was unknown if the patient experienced any additional symptoms/events. No treatment information was provided No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.